Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-020417
Filing Date
2025-02-14
Accepted
2025-02-14 07:55:55
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10103
2 EX-99.A ck0001669811-ex99_a.pdf EX-99.A 92503
  Complete submission text file 0000950170-25-020417.txt   139411
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Subject) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91583 | Film No.: 25623275
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 CLARENDON STREET BOSTON MA 02116
Business Address 200 CLARENDON STREET BOSTON MA 02116 617-516-2000
Bain Capital Life Sciences Fund, L.P. (Filed by) CIK: 0001687968 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A